A new regulatory road-map for Alzheimer's disease drug development

Current Alzheimer Research

Volumn 11, Issue 3, 2014, Pages 215-220

  Becker, Robert E ^a,b   Greig, Nigel H ^b  

^a Aristea Translational Medicine Corp   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer clinical trials; Alzheimer's disease; Dementia trials; Drug approval process; Drug development; Drug regulations

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; DISEASE COURSE; DRUG APPROVAL; DRUG DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; HUMANS;

EID: 84897389736     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501103140329210642     Document Type: Article

References (28)

1. Becker RE, Greig NH, Giacobini E, Schneider L, Ferrucci L. Developing Alzheimer's disease drugs in the public interest: a new road-map for drug development, Nature Rev. Drug Discov 13(2): 156 (2014).
2. Becker RE, Greig NH. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 5: 347-57 (2008).
3. Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimers Dis 15: 303-25 (2008).
4. Becker RE, Greig NH. Alzheimer's disease drug development: old problems require new priorities. CNS Neurol Disord Drug Targets 7: 499-511 (2008).
5. Becker RE, Greig NH. Neuropsychiatric clinical trials: should they accommodate to 'real-world' practices or set standards for clinical practices? J Clin Psychopharm 29: 56-64 (2009).
6. Becker RE, Unni LK, Greig NH. Resurrecting clinical pharmacology as a context for Alzheimer disease drug development. Curr Alzheimer Res 6: 79-81 (2009).
7. Becker RE, Greig NH. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 7: 642-51 (2010).
8. Becker RE, Greig NH. Neuropsychiatric clinical trials: lost in translation. Sci Transl Med 2(61): 61rv6 (2010).
9. Becker RE, Greig NH. Fire in the ashes: can failed Alzheimer's drugs succeed with second chances? Alzheimers Dement 9: 50-7 (2013).
10. Becker RE, Greig NH. Was phenserine a failure or were investigators mislead by methods? Curr Alzheimer Res 9: 1174-81 (2012).
11. Terra SG, Johnson JA. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward. Am J Cardiovasc Drugs 2: 287-96 (2002).
12. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8:587-96 (2011).
13. Kozaue N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368: 1169-71 (2013).
14. U.S. Food and Drug Administration. FDA Webinar: Draft Guidance For Industry On Alzheimer's Disease: Developing Drugs For The Treatment Of Early Stage Disease; Availability-March 28, 2013http://www.fda.gov/Drugs/ucm345077.htm (last viewed on December 6, 2013).
15. Mullard A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev Drug Discov 11: 657-60 (2012).
16. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 12: 1060-5 (2011).
17. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-23 (2005).
18. Bradley N. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, et al. What did STAR*D teach us? Results from a largescale, practical, clinical trial for patients with depression. Psychiatr Serv 60: 1439-45 (2009).
19. Kozauer NA. FDA Webinar: Early Alzheimer Alzheimer's Disease Draft Guidance, March 28, 2013. http://www.fda.gov/ downloads/Training/GuidanceWebinars/UCM345555.pdf(last viewed on December 6, 2013).
20. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of f-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69: 98-106 (2012).
21. Jack CR Jr., Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain B-amyloid load approaches a plateau. Neurology 80: 890-6 (2013).
22. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic Traumatic Encephalopathy in Athletes: ProgressiveTauopathy following Repetitive Head Injury. J Neuropathol Exp Neurol 68: 709-735 (2009).
23. Zahs KR, Ashe KH. [-amyloid oligomers in aging and Alzheimer's disease. Front Aging Neurosci 5: 28 1-5 (2013).
24. Morris JM, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, et al. Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. Clin Investig (London) 2: 975-984 (2010)
25. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov 11: 565-6 (2012).
26. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 23: 18-23 (2010).
27. Katz, R. FDA: evidentiary standards for drug development and approval. NeuroRx1: 307-16 (2004).
28. Cummings J. Phase 2A Trial of Bexarotene in Patients with Alzheimer's Disease. The AlzForum. June 21, 2013; http://www.alzforum.org/pap/annotation.asp?powID=147562(last viewed on December 6, 2013).